Regeneron drug for rare bone-growth disease earns FDA approval

Revelation News Editorial DeskAugust 19, 2026

Source Summary

Regeneron Pharmaceuticals has received FDA approval for a drug treating an ultra-rare disease characterized by abnormal bone formation in unintended locations.

Read the Source

STAT News ↗

NASDAQ:REGNLive chart

Trading trends

The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.

Recent SEC-reported share and derivative transactions in REGENERON PHARMACEUTICALS, INC..

Insider activity sentiment

Neutral

BearishNeutralBullish

0 discretionary purchases · 0 discretionary sales

Confidence: Low

Informative buyNon-informative buyInformative sellNon-informative sell

Insiders	Activity	Description	Shares	Avg. price / share	Est. value	Trade date
Co-Chief Scientific OfficerMURPHY ANDREW J	Non-informative sell	Common StockReported 10b5-1 plan (S)	6	$753.76	$4,523	Oct 14, 2026
Co-Chief Scientific OfficerMURPHY ANDREW J	Non-informative sell	Common StockReported 10b5-1 plan (S)	35	$755.91	$26,457	Oct 14, 2026
Co-Chief Scientific OfficerMURPHY ANDREW J	Non-informative sell	Common StockReported 10b5-1 plan (S)	16	$757.68	$12,123	Oct 14, 2026
Co-Chief Scientific OfficerMURPHY ANDREW J	Non-informative sell	Common StockReported 10b5-1 plan (S)	24	$758.16	$18,196	Oct 14, 2026
Co-Chief Scientific OfficerMURPHY ANDREW J	Non-informative sell	Common StockReported 10b5-1 plan (S)	14	$759.96	$10,639	Oct 14, 2026

As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.

Short interest

Open short positions reported twice monthly; this is not daily short-sale volume.

Earnings

Recent reported earnings per share compared with the analyst consensus available from Nasdaq.

Comments

No published comments yet.

Owner	Activity	Change	Shares held	Value (thousands)	Reported
Blackrock, Inc.	Buy	165,771 (1.853%)	9,113,506	$7,464,782	6/30/2026
Vanguard Group Inc	Buy	26,884 (0.297%)	9,075,153	$7,433,367	12/31/2025
Vanguard Capital Management Llc	Sell	-25,154 (-0.378%)	6,629,759	$5,430,369	6/30/2026
Dodge & Cox	Buy	412,899 (9.261%)	4,871,137	$3,989,900	6/30/2026
State Street Corp	Buy	170,210 (3.649%)	4,834,688	$3,960,045	6/30/2026
Invesco Ltd.	Buy	35,556 (0.911%)	3,940,665	$3,227,759	6/30/2026
Jpmorgan Chase & Co	Sell	-537,607 (-12.468%)	3,774,199	$3,091,409	6/30/2026
Vanguard Portfolio Management Llc	Buy	1,454,539 (84.528%)	3,175,313	$2,600,867	6/30/2026
Franklin Templeton Inc	Buy	49,768 (1.828%)	2,771,839	$2,270,386	6/30/2026
Geode Capital Management, Llc	Buy	18,078 (0.693%)	2,625,810	$2,150,775	6/30/2026
Nuveen, Llc	Sell	-45,090 (-2.183%)	2,019,974	$1,654,541	6/30/2026
Loomis Sayles & Co L P	Sell	-53,138 (-2.779%)	1,859,172	$1,522,829	6/30/2026

Settlement date	Short interest	Avg. daily volume	Change vs. previous report	Days to cover
Sep 30, 2026	2,150,303	863,842	-14.89%	2.49
Sep 15, 2026	2,526,446	571,271	-1.00%	4.42
Aug 31, 2026	2,552,029	662,864	+6.51%	3.85
Aug 14, 2026	2,396,152	760,654	-29.23%	3.15
Jul 31, 2026	3,385,841	858,662	-3.29%	3.94
Jul 15, 2026	3,501,203	741,224	+0.19%	4.72
Jun 30, 2026	3,494,420	1,199,840	+5.75%	2.91
Jun 15, 2026	3,304,329	968,690	—	3.41

Fiscal quarter	Reported	EPS	Consensus	Surprise
Jun 2026	Jul 30, 2026	12.53	8	+56.62%
Mar 2026	Apr 29, 2026	7.50	6.28	+19.43%
Dec 2025	Jan 30, 2026	9.30	8.28	+12.32%
Sep 2025	Oct 28, 2025	9.63	7.52	+28.06%

Source Summary

Read the Source

NASDAQ:REGN — Live chart

Insider activity sentiment

Comments

Related stories

Ionis Wins FDA Approval for Zanvastro, First Disease-Modifying Treatment for Alexander Disease

Scholar Rock Wins FDA Approval for Isembyld, First Drug to Target SMA Muscle Loss

FDA Approves First Treatment for Rare Brain Disorder Alexander Disease

Comments

Insider activity sentiment

NASDAQ:REGNLive chart